The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Epkinly (epcoritamab-bysp) on March 27, 2026. This approval, sponsored by Genmab US, Inc., indicates a regulatory action pertaining to the drug's demonstrated effectiveness.
Background
Epcoritamab, known by its brand name Epkinly, is a therapeutic agent developed by Genmab US, Inc. The recent FDA action was a supplemental application, specifically classified as an efficacy supplement. Supplemental applications allow for changes to an approved product, such as new indications, dosing regimens, or manufacturing changes, without requiring a completely new drug application.
What this means
A supplemental efficacy approval signifies that the FDA has reviewed and accepted new or additional data supporting the effectiveness of Epkinly. While the specific details of the updated indication or patient population are not provided in this regulatory notice, such approvals typically expand the drug's approved uses, refine its target patient population, or incorporate more comprehensive efficacy data into its official labeling. For clinicians, this means updated information regarding Epkinly's demonstrated benefits will be available, potentially broadening its clinical utility or refining its application in specific patient groups. This could lead to new treatment options for patients who may benefit from Epkinly. Researchers may find the new data valuable for understanding the drug's full therapeutic potential and informing future studies into its mechanism of action or comparative effectiveness. Patient advocates will be interested in how this approval impacts access and treatment options for patients who could benefit from Epkinly, ensuring that the most current and robust efficacy data guides treatment decisions.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website, specifically the Drugs@FDA database. The event date was March 27, 2026, and the details are publicly accessible on accessdata.fda.gov.